The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | 2-year follow-up of MajesTEC-1: teclistamab in R/R multiple myeloma
Surbhi Sidana, MD, Stanford University, Stanford, CA, discusses the two-year follow-up results of MajesTEC-1 trial (NCT04557098) assessing teclistamab treatment in patients with relapsed/refractory (R/R) multiple myeloma. Dr Sidana highlights the extended duration of response and the reduced infection rates observed over time. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
